Investigation of the Use of Bilirubin Oxidation as a Screening Test for Coronary Artery Disease

DOI Web Site 参考文献30件
  • Yamamoto Masaki
    Kidawara Hospital, Department of Surgery Kochi University, Kochi Medical School, Department of Surgery 2 Center for Photodynamic Medicine, Kochi University
  • Ninomiya Hitoshi
    Toyo University, Department of Civil and Environmental Engineering
  • Yamaguchi Tokio
    Tokyo Medical and Dental University, Department of Biochemical Genetics, Medical Research Institute
  • Kidawara Koichi
    Kidawara Hospital, Department of Surgery
  • Orihashi Kazumasa
    Kochi University, Kochi Medical School, Department of Surgery 2 Center for Photodynamic Medicine, Kochi University
  • Sato Takayuki
    Center for Photodynamic Medicine, Kochi University Kochi University, Kochi Medical School, Department of Cardiovascular Control
  • Inoue Keiji
    Center for Photodynamic Medicine, Kochi University Kochi University, Kochi Medical School, Department of Urology
  • Hanazaki Kazuhiro
    Center for Photodynamic Medicine, Kochi University Kochi University, Kochi Medical School, Department of Surgery 1

この論文をさがす

抄録

Objective: Coronary artery disease (CAD) involves repeated transient ischemia and reperfusion in the myocardium that produces reactive oxygen species causing bilirubin oxidation and biopyrrins production. This study investigates the urinary-biopyrrin (u-biopyrrin) levels of CAD patients, to assess their utility as a parameter for CAD assessment. Materials and Methods: We retrospectively analyzed 32 CAD patients, 11 non-CAD patients, and 5 post-revascularization patients (PRP). The 32 CAD patients were further divided into subgroups based on the number of vessels involved, namely, 3- or 2-vessel disease (VD) (n=25 and 7, respectively) and the type of myocardial ischemia symptom, namely, unstable angina pectoris (UAP), effort angina pectoris (EAP), or silent myocardial ischemia (SMI) (n=9, 14, and 9, respectively). Participant data were compared between each group. To compare the association between the severity of CAD and u-biopyrrin value, the severity of CAD was evaluated using SYNTAX I and SYNTAX II scores. Results: The u-biopyrrin levels were higher in the CAD group than in the non-CAD and PRP groups. There was no significant difference in u-biopyrrin value between the 3-VD and 2-VD patients, or among UAP, EAP, and SMI patients. The anatomical and clinical severity scores indicated by SYNTAX I and II scores were moderately correlated with u-biopyrrin levels and treatment risk in the receiver operating characteristic curve analysis, the u-biopyrrin level showed a cut-off value of 2.1 mmol/g.cre (AUC, 0.739; sensitivity, 43.75%; specificity, 93.75%). Conclusions: The u-biopyrrin levels were greater in CAD patients than in non-CAD and PRP patients. U-biopyrrin levels moderately correlated with the anatomical and clinical severity of CAD.

収録刊行物

参考文献 (30)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ